Weight-loss shots carry two and a half times the risk of a bone-softening disease

Adults taking GLP-1 receptor agonists for type 2 diabetes and obesity developed osteomalacia, a bone-softening disease, at more than double the rate of matched patients who were not on the drugs. Over five years, 0.2% of GLP-1 users developed the condition compared with 0.1% of controls, a risk ratio of 2.55, according to research presented at the American Academy of Orthopaedic Surgeons’ 2026 annual meeting in New Orleans.

The study tracked 73,483 patients in each group, comparing people treated with semaglutide, liraglutide, dulaglutide or exenatide against demographically matched patients with the same underlying conditions who were not exposed to the drug class. Osteomalacia showed the largest relative jump of any bone or joint condition the researchers measured.

Osteomalacia is a mineralization defect, not a density loss

Osteomalacia is frequently confused with osteoporosis, but the two conditions work through different mechanisms. Osteoporosis is a loss of bone density and mass, leaving bones thinner and more porous. Osteomalacia is a failure of the mineralization process itself: the collagen scaffold of bone forms normally, but not enough calcium and phosphate get deposited into it, leaving bone tissue soft and pliable rather than brittle. According to a clinical overview hosted on the National Institutes of Health’s NCBI Bookshelf, the condition typically stems from vitamin D deficiency or disrupted calcium and phosphate metabolism, and it produces diffuse bone pain, muscle weakness and a heightened risk of fractures, most often centered in the hips, pelvis and legs. Left untreated, the softened bone can bow under normal body weight in ways dense but porous osteoporotic bone typically does not.

That distinction matters for interpreting the new data, because it means GLP-1 drugs are not simply accelerating ordinary age-related bone loss. Something about long-term use of the drug class appears tied to a breakdown in how bone mineralizes in the first place, a mechanism the researchers did not fully explain but flagged as worth monitoring.

The researcher behind the numbers says the data are only now catching up to the drugs

The analysis was led by Muaaz Wajahath of Michigan State University’s College of Human Medicine, who presented the findings alongside colleagues at the AAOS meeting. Wajahath framed the study as an early look at a question that simply could not be answered until now, since the GLP-1 drug class only reached mass adoption for weight loss in the past several years. “We are just now reaching the precipice where five- and 10-year follow-up data are becoming available for patients taking GLP-1 medications,” Wajahath said, according to Clinical Pain Advisor’s coverage of the presentation.

Wajahath also framed the clinical response the data should prompt, rather than treating the numbers as a reason to avoid the drugs outright. “Whenever you have a patient who is prone to osteoporosis, gout or osteomalacia, clinicians should consider bone health surveillance and monitor for delayed-onset complications in at-risk populations,” Wajahath said, a recommendation reported by Rheumatology Advisor.

Osteoporosis and gout also rose, but by smaller margins

Osteomalacia was not the only skeletal or joint condition the researchers tracked. Osteoporosis occurred in 4.1% of GLP-1 users at five years compared with 3.2% of matched controls, a risk ratio of 1.29. Gout appeared in 7.4% of GLP-1 users compared with 6.6% of controls, a smaller relative increase with a risk ratio of 1.12. Both increases were statistically significant in the matched-cohort design, but neither approached the relative jump seen in osteomalacia, according to the study details carried by Drugs.com’s MedNews summary of the AAOS presentation.

The gap between osteomalacia’s 2.55 risk ratio and gout’s 1.12 risk ratio illustrates why the researchers singled out bone mineralization as the standout finding rather than lumping all three conditions together as a generic “bone and joint” warning. A condition that is rare in absolute terms, affecting roughly 1 in 500 patients on the drugs versus 1 in 1,000 among controls, can still carry the largest proportional increase even though osteoporosis and gout affected far more patients overall.

What the study can and cannot show

The research compared large, matched groups of patients rather than randomly assigning some people to take GLP-1 drugs and others not to, which means it can identify an association but cannot on its own prove that the medications caused the bone changes. Patients severe enough in their diabetes or obesity to be prescribed a GLP-1 drug may differ from matched controls in ways the matching process did not fully capture, including nutritional status, physical activity or underlying vitamin D levels that independently affect bone mineralization. The original findings, presented as a conference abstract at the American Academy of Orthopaedic Surgeons’ 2026 annual meeting press kit, have not yet gone through the full peer-review process that a published journal article requires.

Even with those caveats, the size of the two matched cohorts, more than 73,000 patients on each side, gives the comparison more statistical weight than the smaller trial populations that have driven most previous safety data on the drug class. Rapid, large-scale weight loss is already known to reduce bone density independent of any specific drug, since bone tissue responds to the mechanical load of body weight; losing that load quickly can itself weaken bone. Untangling how much of the new signal comes from the GLP-1 mechanism itself, and how much comes from the weight loss the drugs are designed to produce, is a question the researchers said longer follow-up data will need to answer.

For now, the recommendation Wajahath’s team is making is surveillance rather than avoidance: patients on long-term GLP-1 therapy who already carry risk factors for bone disease, including older age, low vitamin D or a personal history of fractures, are the group the researchers say clinicians should watch most closely as five- and ten-year data continues to accumulate.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview